NCT01910480View on ClinicalTrials.gov

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
Interventions
DRUG

NBI-98854 50 mg capsule once daily

DRUG

Ketoconazole 400 mg (200 mg twice daily)

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY